Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Has One Hemophilia Winner On It Hands – But Fitusiran’s Fate Remains Unclear

Efanesoctocog Alfa Filed Last Month

Executive Summary

Sanofi is hoping to have two paradigm-changing hemophilia drugs on the market by 2025 – but one of these, fitusiran, must first prove its safety and efficacy at a lower dose.

You may also be interested in...



Alnylam Stays Mum On APOLLO-B Amid Anticipation Over Major Readout

The company announced a respectable increase in second quarter sales and expects to announce topline results within the next three weeks for the Phase III trial of Onpattro in ATTR-CM.

Japan-Specific Approval For Hemlibra In Acquired Hemophilia A

Hemlibra receives new approval in Japan intractable disease indication, while positive Phase III results in mild/moderate disease hemophilia A will support a planned EU filing in this setting. 

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: setback for a COVID-19 candidate; Chinese biotechs move into mRNA; Sanofi’s strategic moves into hemophilia; Orion’s deal for its novel prostate cancer candidate; and Roche’s evolving approach to platform deals.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel